Home › Research › Clinical trials
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
C Mallinckrodt, Y Tian, P S Aisen, F Barkhof, S Cohen, G Dent, O Hansson, K Harrison et al.. The journal of prevention of Alzheimer's disease, 2023
Topic: Drug trials: efficacy and safety
Plain-language summary
Post-hoc analyses showed that outcomes in the ENGAGE high-dose group were affected by an imbalance in a small number of patients with extremely rapid progression and by lower exposure to the target dose of 10 mg/kg. These factors were confounded and present in early enrolled patients but were not present in later-enrolled patients who were randomized to the target dosing regimen of 10 mg/kg after titration. Neither baseline characteristics nor amyloid-related imaging abnormalities contributed to the difference in results between the high-dose arms. Results were consistent across studies in later enrolled patients in which the incidence of rapidly progressing patients was balanced across treatment arms.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mallinckrodt, C., Tian, Y., Aisen, P. S., Barkhof, F., Cohen, S., Dent, G., et al. (2023). Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2023.6
Vancouver
Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Cohen S, Dent G, et al. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. The journal of prevention of Alzheimer's disease. 2023. doi:10.14283/jpad.2023.6. PMID: 36946443.
BibTeX
@article{mallinckrodt2023-36946443,
author = {Mallinckrodt, C and Tian, Y and Aisen, P S and Barkhof, F and Cohen, S and Dent, G and Hansson, O and Harrison, K and others},
title = {{Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2023},
doi = {10.14283/jpad.2023.6},
pmid = {36946443},
url = {https://doi.org/10.14283/jpad.2023.6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Post-hoc analyses showed that outcomes in the ENGAGE high-dose group were affected by an imbalance in a small number of patients with extremely rapid progression and by lower exposure to the target dose of 10 mg/kg.
- These factors were confounded and present in early enrolled patients but were not present in later-enrolled patients who were randomized to the target dosing regimen of 10 mg/kg after titration.
- Neither baseline characteristics nor amyloid-related imaging abnormalities contributed to the difference in results between the high-dose arms.
- Results were consistent across studies in later enrolled patients in which the incidence of rapidly progressing patients was balanced across treatment arms.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designpost-hoc analysis
- Participants1,638
- Evidence strengthHigh
How this study scored 80/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 45 of the 56 points we could judge it on, which is 80 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,638 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36946443) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 45 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 45 of the 56 points we could judge it on is 80 out of 100. |
| Total | 80 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.